Health & bio

Gilead's Once-Daily HIV Therapy Granted Priority Review

Bictegravir plus lenacapavir once-daily NDA received priority review April 29. Potential paradigm shift toward simplified once-daily oral HIV management.

Primary sources · 1

FDA

← View the full 2026-04-30 (Thursday) issue

What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →